This study is a randomized, double blind, controlled, French multicenter study (11 centers). The investigators plan to include 138 patients with persistent symptoms in schizophrenia. Sixty-nine subjects will receive active tDCS and 69 subjects will receive sham tDCS (placebo). Hypothesize is a lasting effect of active tDCS on the schizophrenic symptoms as measured by the number of responders, defined as a decrease of at least 25% of symptoms as measured by a standardized clinical scale score (PANSS) between baseline and after the 10-session tDCS regimen.